Human TRAIL/TNFSF10 Quantikine ELISA Kit | R&D Systems DTRL00 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

ELISA/assay

product name :

Human TRAIL/TNFSF10 Quantikine ELISA Kit

catalog :

DTRL00

quantity :

1 Kit

price :

655 USD

citations: 37

Reference
Bate K, Genetzakis E, Vescovi J, Gray M, Celermajer D, McGuire H, et al. Vascular Cytokines and Atherosclerosis: Differential Serum Levels of TRAIL, IL-18, and OPG in Obstructive Coronary Artery Disease. Biomolecules. 2024;14: pubmed publisher
Kuehnle N, Osborne S, Liang Z, Manzano M, Gottwein E. CRISPR screens identify novel regulators of cFLIP dependency and ligand-independent, TRAIL-R1-mediated cell death. Cell Death Differ. 2023;30:1221-1234 pubmed publisher
Ravichandran S, Grubbs G, Tang J, Lee Y, Huang C, Golding H, et al. Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures. Sci Adv. 2021;7:eabi6533 pubmed publisher
Kuo M, Chang W, Wu L, Tsai Y, Hsu Y. Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Proximal Tubular Epithelial Cells through miR-545-3p-TNFSF10. Biomolecules. 2021;11: pubmed publisher
Hadad E, Rudnick Glick S, Itzhaki E, Avivi M, Grinberg I, Elias Y, et al. Engineering of Doxorubicin-Encapsulating and TRAIL-Conjugated Poly(RGD) Proteinoid Nanocapsules for Drug Delivery Applications. Polymers (Basel). 2020;12: pubmed publisher
Eom Y, Akter R, Li W, Lee S, Hwang S, Kim J, et al. M1 Macrophages Promote TRAIL Expression in Adipose Tissue-Derived Stem Cells, Which Suppresses Colitis-Associated Colon Cancer by Increasing Apoptosis of CD133+ Cancer Stem Cells and Decreasing M2 Macrophage Population. Int J Mol Sci. 2020;21: pubmed publisher
Cheng L, Yu H, Wrobel J, Li G, Liu P, Hu Z, et al. Identification of pathogenic TRAIL-expressing innate immune cells during HIV-1 infection in humanized mice by scRNA-Seq. JCI Insight. 2020;5: pubmed publisher
Masuda A, Isobe Y, Sugimoto K, Yoshimori M, Arai A, Komatsu N. Efficient recruitment of c-FLIPL to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma. Cancer Sci. 2020;111:807-816 pubmed publisher
Schenck E, Ma K, Price D, Nicholson T, Oromendia C, Gentzler E, et al. Circulating cell death biomarker TRAIL is associated with increased organ dysfunction in sepsis. JCI Insight. 2019;4: pubmed publisher
Rossignoli F, Spano C, Grisendi G, Foppiani E, Golinelli G, Mastrolia I, et al. MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Theranostics. 2019;9:436-448 pubmed publisher
Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, et al. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep. 2019;9:1788 pubmed publisher
Arcidiacono M, Rimondi E, Maietti E, Melloni E, Tisato V, Gallo S, et al. Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. PLoS ONE. 2018;13:e0203716 pubmed publisher
Tisato V, Gallo S, Melloni E, Celeghini C, Passaro A, Zauli G, et al. TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress. Mediators Inflamm. 2018;2018:9629537 pubmed publisher
Yang J, Leblanc F, Dighe S, Hamele C, Olson T, Feith D, et al. TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood. 2018;: pubmed publisher
Morano D, Rolfo A, Tisato V, Farina A, Rimondi E, Scutiero G, et al. Lower maternal serum tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in early preeclampsia. A retrospective study. Pregnancy Hypertens. 2018;12:1-5 pubmed publisher
Wagner J, Kline C, Zhou L, Khazak V, El Deiry W. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. J Exp Clin Cancer Res. 2018;37:11 pubmed publisher
Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J, et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016;167:419-432.e16 pubmed publisher
Remuzgo Martínez S, Genre F, López Mejías R, Ubilla B, Mijares V, Pina T, et al. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. Sci Rep. 2016;6:29713 pubmed publisher
Burger J, Landau D, Taylor Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589 pubmed publisher
Mohr A, Yu R, Zwacka R. TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. BMC Cancer. 2015;15:494 pubmed publisher
Zhou C, Long Y, Yang H, Zhu C, Ma Q, Zhang Y. TRAIL Is Decreased Before 20 Weeks Gestation in Women with Hypertensive Disorders of Pregnancy. PLoS ONE. 2015;10:e0128425 pubmed publisher
Choi S, Lee Y, Kwak P, Lee J, Kim S, Lee S, et al. Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas. Cancer Gene Ther. 2015;22:302-11 pubmed publisher
Kang S, Kang D, Bakhtiar Ul Islam S, Je S, Kim J, Song J. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest. Cell Signal. 2015;27:1214-24 pubmed publisher
Teng J, Hejazi S, Badr C, Tannous B. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells. 2014;32:2021-32 pubmed publisher
Ray A, Tian Z, Das D, Coffman R, Richardson P, Chauhan D, et al. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia. 2014;28:1716-24 pubmed publisher
Zhang Y, Patel B, Dey A, Ghorani E, Rai L, Elham M, et al. Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function. J Immunol. 2012;188:1002-10 pubmed publisher
Bem R, Bos A, Wösten van Asperen R, Bruijn M, Lutter R, Sprick M, et al. Potential role of soluble TRAIL in epithelial injury in children with severe RSV infection. Am J Respir Cell Mol Biol. 2010;42:697-705 pubmed publisher
Niessner A, Hohensinner P, Rychli K, Neuhold S, Zorn G, Richter B, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009;30:789-96 pubmed publisher
Secchiero P, Lamberti G, Corallini F, Melloni E, Guarnotta C, Sebastiani A, et al. Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye. J Cell Physiol. 2009;218:199-204 pubmed publisher
Secchiero P, Melloni E, Corallini F, Beltrami A, Alviano F, Milani D, et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells. 2008;26:2955-63 pubmed publisher
Chamoux E, Houde N, L Ériger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol. 2008;216:536-42 pubmed publisher
Hoffmann O, Priller J, Prozorovski T, Schulze Topphoff U, Baeva N, Lunemann J, et al. TRAIL limits excessive host immune responses in bacterial meningitis. J Clin Invest. 2007;117:2004-13 pubmed
Corallini F, Celeghini C, Rizzardi C, Pandolfi A, Di Silvestre S, Vaccarezza M, et al. Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro. J Cell Physiol. 2007;212:89-95 pubmed
Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, Williams B, et al. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family. Clin Pharmacol Ther. 2007;81:354-61 pubmed
Claessens Y, Fontenay M, Pène F, Chiche J, Guesnu M, Hababou C, et al. Erythropoiesis abnormalities contribute to early-onset anemia in patients with septic shock. Am J Respir Crit Care Med. 2006;174:51-7 pubmed
Gibellini D, Vitone F, Schiavone P, Re M. HIV-1 tat protein and cell proliferation and survival: a brief review. New Microbiol. 2005;28:95-109 pubmed
Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol. 2005;166:557-63 pubmed

product information

master code :

DTRL00

SKU :

DTRL00

product name :

Human TRAIL/TNFSF10 Quantikine ELISA Kit

unit size :

1 Kit

description :

The Human TRAIL/TNFSF10 Quantikine ELISA Kit from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human TRAIL/TNFSF10 in cell culture supernates (50 ul), cell lysates (50 ul), serum (50 ul), edta plasma (50 ul), heparin plasma (50 ul), saliva (25 ul).

target :

TRAIL/TNFSF10

category :

ELISAs

species :

Human

specificity :

Natural and recombinant human TRAIL

gene symbol :

TNFSF10

kit type :

Solid Phase Sandwich ELISA

assay length :

4.5 hours

elisaSampleTypes :

Cell Culture Supernates (50 uL), Cell Lysates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL), Saliva (25 uL)

elisaSensitivity :

7.87 pg/mL

elisaRange :

15.60 - 1000 pg/mL

top caption :

Human TRAIL/TNFSF10 ELISA Cell Culture Supernate/Cell Lysate/Saliva Standard Curve

applications :

ELISA

USD :

655 USD

product details :

The Quantikine Human TRAIL Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human TRAIL in cell culture supernates, serum, plasma, cell lysates, and saliva. It contains NS0-expressed recombinant human TRAIL and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human TRAIL showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for natural human TRAIL

alt names :

Apo-2 ligand, APO2L, Apo-2Ltumor necrosis factor (ligand) family, member 10, APO2Ltumor necrosis factor apoptosis-inducing ligand splice variant delta, CD253, CD253 antigen, Protein TRAIL, TL2, TNF-related apoptosis-inducing ligand, TNFSF10, TRAILTNF-related apoptosis inducing ligand TRAIL, tumor necrosis factor (ligand) superfamily, member 10, tumor necrosis factor ligand superfamily member 10

storage :

Store the unopened product at 2 - 8 ░C. Do not use past expiration date.